Mycophenolate Mofetil in Dermatology

Introduction to Mycophenolate Mofetil

The American Academy of Dermatology conditionally recommends mycophenolate mofetil (MMF) as an off-label, steroid-sparing immunosuppressant for refractory moderate-to-severe atopic dermatitis and autoimmune blistering diseases, particularly pemphigus vulgaris and bullous pemphigoid, when first-line therapies have failed 1, 2, 3

The American Academy of Dermatology recommends using MMF for adults with refractory moderate-to-severe atopic dermatitis who have failed conventional systemic therapies 1, 2, 3
Expect a delayed onset of action: clinical improvement typically begins after 10 weeks, with efficacy equal to cyclosporine by that time 4
MMF demonstrates longer clinical remission after discontinuation compared to cyclosporine 4
In one retrospective analysis, 85% of patients reported improvement within the first month, and 50% achieved complete disease clearance 4
Add MMF 2-3 g/day immediately at treatment initiation as a steroid-sparing agent alongside prednisolone 1 mg/kg/day for pemphigus vulgaris 5
MMF is preferred over cyclophosphamide in some contexts due to comparable efficacy with potentially fewer severe toxicities 5, 6

Start at 500 mg twice daily and increase by 500 mg weekly to reach target dose of 1000 mg twice daily (2 g/day) 7
For severe autoimmune blistering diseases, doses may range from 2-3 g/day in divided doses 4, 5
In select cases requiring higher immunosuppression, doses up to 1500 mg twice daily (3 g/day) may be used if tolerated 7

MMF inhibits inosine monophosphate dehydrogenase (IMPDH), blocking the de novo purine biosynthesis pathway 4, 7, 8
This selectively affects B-cells and T-cells, which lack compensatory purine salvage mechanisms 4, 8

Monitor CBC and liver function tests every 2-4 weeks initially, then monthly once stable 7
Watch for leukopenia, anemia, and thrombocytopenia 4, 7, 8

Gastrointestinal symptoms (nausea, vomiting, abdominal cramping, diarrhea) are most common, occurring in up to 35% of patients 4, 8
Leukopenia, anemia, and thrombocytopenia can occur but are rare in dermatology patients 4, 8
Theoretical increased susceptibility to viral and bacterial infections exists 4

MMF shows slower onset compared to cyclosporine but longer remission duration after discontinuation 4
MMF demonstrates similar efficacy to azathioprine in bullous pemphigoid with different toxicity profiles 6
A randomized controlled trial showed no significant differences in efficacy or adverse events between pulsed cyclophosphamide and MMF in pemphigus vulgaris 5
For pemphigus vulgaris, MMF's steroid-sparing effect appears greater than cyclophosphamide but evidence quality is limited 6